The Scope E-Newsletter
From the Dean's Office
In the Spotlight
Dr. Wallace Practices the GSM Mission in the Republic of Moldova
New Dedicated Heart Hospital Enhances Fellowship Programs
First-Year Resident Dr. Helms Receives Teaching Award
Dr. Boyd Inspires AVID Nashville High School Students
Surgery Resident Dr. Jones Gains Third-World Medical Experience
Dr. Lawson Selected for New Nestle Nutrition Fellowship
Medical Simulation Center Examines New Virtual Technology
Rinehart Becomes Distinguished Anesthesiology Residency Coordinator
News
New Resident and Fellow Assistance Program Now Available
2010 Torch Campaign Co-Chairs Named
Compliance Update: Reimbursement and Privacy
Continuing Medical and Dental Education
CME-Certified Dermatology Meeting, September 17
Scholarly Activity
Pathology Resident Dr. Bruker Presents ODAM Research in Beijing
Misty Long Participates in Elite PET/CT Symposium
Read all articles in this issue of The Scope
Misty Long Participates in Elite PET/CT Symposium
The 3rd Annual Best Practices in PET/CT Symposium in Sonoma, California, brought together 21 of the U.S. and Canada's leading experts in PET/CT imaging and clinical oncology, and Misty Long, PET/CT Research Technologist, Molecular Imaging and Translational Research Program, was among them.
The conference, held April 8-9, invited imaging physicians, medical and radiation oncologists, physicists, and technologists from a variety of practice settings to discuss this year's topic, "PET/CT Imaging in Monitoring Response to Therapy." Long said the symposium provides a setting for roundtable discussions to provide useful insights regarding current and anticipated needs of the PET/CT community.
An important question discussed in nuclear medicine imaging is how often and when a patient should be scanned following oncology treatment. Long said that at the UT Graduate School of Medicine, research protocols are already in place, set in collaboration with Wahid Hanna, MD, Professor of Medicine and Chief of the Hematology/Oncology Division. In previous research studies, PET predicts the response to chemotherapy in non-small cell lung cancer patients as early as two weeks after the initiation of chemotherapy. Her team has previously published several papers in response to their research and methods for imaging, including, "Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT," published in the Journal of Nuclear Medicine, which shows that imaging at one and three weeks after the initiation of chemotherapy allowed prediction of the response to therapy.
"Many people do not realize that the previous director of the imaging program, my former boss, Dr. David Townsend, actually invented the PET/CT scanner," Long said. "I have been blessed to use the latest scanner and imaging technology here at the Graduate School of Medicine."
